The next objective in the treatment of this cancer includes the full recruitment of the immune system activity by targeting co-inhibitory and co-stimulatory molecules in sequence or in combination with the targeted therapies such as the BRAF/MEK inhibitors, the approaches to improve the function of innate immune response, the cytokines, the IDO inhibition, the adoptive cell transfer and T-cell engineering, the therapeutic vaccines in combination with ongoing therapeutic approaches (NCT02178722; NCT02327078; NCT01656642; NCT02130466; NCT02263508). Here, IDO1 is linked to cancer.